After its COVID-19 vaccine got approved in March, the investment logic is different. This article analyzed the key catalysts of Zhifei (agency business, COVID-19 vaccine) and thoughts on valuation.
SUMMARY
(Sign Up to Access)
Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:
Unlock research summaries
Follow top, independent analysts
Receive personalised alerts
Access Analytics, Events and more
Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.